Welcome to our dedicated page for LAVA Therapeutics N.V. SEC filings (Ticker: LVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to historical SEC filings for LAVA Therapeutics N.V. (formerly Nasdaq: LVTX), a clinical-stage immuno-oncology company that developed bispecific gamma-delta T cell engagers using its Gammabody® platform. These documents trace both the company’s scientific focus and the corporate steps that led to its acquisition by XOMA Royalty Corporation and removal from the Nasdaq Global Select Market.
For investors and researchers, Forms 10-K, 10-Q and related reports (where applicable) offer detail on LAVA’s pipeline, including the internal candidate LAVA‑1266 for CD123+ hematologic malignancies and partnered programs JNJ‑89853413 with Johnson & Johnson and PF‑08046052 with Pfizer Inc. These filings typically describe the mechanism of action of LAVA’s bispecific gamma-delta T cell engagers, clinical trial status, risk factors, and collaboration economics.
The series of Form 8-K filings in 2025 is especially important for understanding LVTX as a former public company. They document entry into the Share Purchase Agreement with XOMA Royalty Corporation, amendments to the offer terms, the progress and results of the tender offer, the subsequent offering period, and the resulting change in control. Additional 8‑Ks describe shareholder votes at an extraordinary general meeting, LAVA’s notice of intent to voluntarily delist, Nasdaq’s suspension of trading and filing of Form 25 to remove LVTX from listing and registration, and LAVA’s stated intention to file Form 15 to terminate its reporting obligations.
Stock Titan’s platform surfaces these filings with AI-powered summaries that highlight key terms, conditions and implications, helping users quickly interpret complex documents such as the Share Purchase Agreement, CVR Agreement descriptions, and restructuring disclosures. You can review historical ownership and governance changes, transaction structures, and program-level information as reported directly to the SEC, while AI-generated insights point to the sections most relevant to LVTX’s transition from an independent Nasdaq-listed issuer to a majority-owned subsidiary of XOMA Royalty Corporation.
LAVA Therapeutics N.V. has effectively been acquired by XOMA Royalty Corporation through a completed tender offer and is transitioning off the public markets. Buyer agreed to purchase all common shares at $1.04 per share plus one contingent value right (CVR), which may provide additional cash payments under a separate CVR agreement. The offer, as extended, expired on November 12, 2025, with 22,877,463 shares (about 87% of shares) validly tendered and accepted for payment.
A subsequent offering period through November 20, 2025 brought total tenders to 23,956,708 shares, about 91.1% of shares outstanding, including 1,079,245 shares tendered during this later window. Trading in LAVA’s shares on Nasdaq was suspended prior to the market opening on November 21, 2025, and Nasdaq filed a Form 25 to remove the listing. The company plans to end its SEC reporting obligations by filing a Form 15 on or about December 1, 2025. Effective November 21, 2025, Stephen Hurly and Fred Powell ceased to be executive officers, with severance terms referenced from LAVA’s prior proxy statement.
LAVA Therapeutics (LVTX) reported the completion of XOMA Royalty Corporation’s tender offer and post-offer reorganization. As of the subsequent closing date, a total of 23,956,708 common shares, representing approximately 91.1% of LAVA’s outstanding shares, were validly tendered and accepted for payment, including 1,079,245 shares (about 4.2%) tendered during the subsequent offering period. The shares ceased trading on Nasdaq prior to the opening on November 21, 2025, and Nasdaq will file a Form 25 to delist and deregister the shares. LAVA and XOMA plan to file Form 15 to terminate registration and suspend LAVA’s reporting obligations, completing LAVA’s transition to a non-reporting, privately held company structure.
LAVA Therapeutics N.V. (LVTX) reported an insider equity transaction by its Chief Financial Officer. On 11/13/2025, the CFO disposed of 65,000 common shares and had 124,700 share options cancelled. Both actions were carried out under a Purchase Agreement between LAVA Therapeutics and XOMA Royalty Corporation.
Each common share was exchanged for $1.04 in cash plus one non-transferable contingent value right (CVR). Each in-the-money option was cancelled in return for cash, based on the excess of $1.04 over the option’s exercise price, and one CVR per underlying share, net of applicable taxes and deductions.
LAVA Therapeutics N.V. reported that a director cancelled an option to buy 33,390 common shares with an exercise price of $0.93 per share on 11/13/2025. The option had been scheduled to expire on 02/12/2035. Under a Purchase Agreement between the company and XOMA Royalty Corporation, the cancellation consideration consists of cash equal to the excess of $1.04 over the per-share exercise price multiplied by the number of shares underlying the option, plus one contingent value right for each in-the-money share. Following this transaction, the reporting person held 0 derivative securities of this type.
LAVA Therapeutics N.V. (LVTX)33,390 common shares with a per share exercise price of $0.93 on 11/13/2025. The option had been exercisable until 02/12/2035. According to a purchase agreement dated 08/03/2025 between the company and XOMA Royalty Corporation, the option was cancelled in exchange for cash and contingent value rights (CVRs). The cash component equals the excess of $1.04 over the option’s exercise price multiplied by the number of underlying shares, plus one CVR for each share underlying the in-the-money option.
LAVA Therapeutics N.V. (LVTX) reported a Form 4 showing that a director’s stock option was fully cancelled in a structured transaction. On 11/13/2025, a share option covering 33,390 common shares with a per share exercise price of $0.93 was disposed of as a derivative security.
The option was cancelled under a Purchase Agreement between LAVA Therapeutics and XOMA Royalty Corporation. In exchange, the reporting person received cash and contingent value rights (CVRs) equal to the excess of $1.04 over the option exercise price, multiplied by the number of underlying shares, plus one CVR for each in-the-money underlying share. Following this transaction, the reporting person reported 0 derivative securities beneficially owned.
LAVA Therapeutics N.V. (LVTX) disclosed on a Form 4 that one of its directors reported the cancellation of a stock option on 11/13/2025. The derivative position was a right to buy common shares at an exercise price of $0.93 per share covering 33,390 underlying common shares, and following the transaction the director held zero of these derivative securities directly.
The filing explains that this option was cancelled under an August 3, 2025 Purchase Agreement between the issuer and XOMA Royalty Corporation. In exchange, the option holder became entitled to cash and contingent value rights, calculated as the excess of $1.04 over the option’s exercise price multiplied by the number of underlying shares, plus one contingent value right for each in-the-money option share.
A director of LAVA Therapeutics N.V. (LVTX) reported a change in holdings on Form 4. On 11/13/2025, a stock option covering 33,390 common shares with a per share exercise price of $0.93 was cancelled. The option was cancelled under a Purchase Agreement between the issuer and XOMA Royalty Corporation. In exchange, the holder became entitled to cash and contingent value rights, calculated as the excess of $1.04 over the option’s exercise price multiplied by the number of underlying shares, plus one CVR for each in-the-money underlying share.
LAVA Therapeutics N.V. director reported a disposition of common shares and related options tied to a Purchase Agreement with XOMA Royalty Corporation. The director disposed of 10,000 common shares on 11/13/2025 and no common shares remained beneficially owned afterward. A stock option covering 33,390 common shares with a per share exercise price of
LAVA Therapeutics N.V. director reported changes in holdings tied to a previously signed Purchase Agreement with XOMA Royalty Corporation. On 11/13/2025, the director disposed of 30,000 common shares, receiving $1.04 in cash per share plus one contingent value right (CVR) for each share. On the same date, a stock option covering 33,390 common shares with a $0.93 exercise price was cancelled under the same agreement in exchange for cash and CVRs, calculated as the excess of $1.04 over the option exercise price multiplied by the number of underlying shares, plus one CVR per in-the-money share.